Abstract
BackgroundEnzalutamide, a next-generation hormonal agent, is approved for the treatment of metastatic castration-resistant prostate cancer (CRPC). Although treatment with enzalutamide results in initial clinical benefit in men with CRPC, resistance...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
